PCSK9 and COVID-19: Uncovering the association between LDL-C and severe COVID-19 is important—proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, a new medication, can significantly decrease LDL-C levels, which might greatly affect prognosis of COVID-19 patients.